In addition to targeted radiation, systemic radiotherapy using radioactive isotopes has been used in the clinic for advanced PCa, with the FDA approvals of Radium-233 for bone metastatic CRPC and the radioligand 177Lu-PSMA-617 for PSMA-positive mCRPC 6, 163. The gene discussed is FOLH1; the disease is posterior cortical atrophy.